Pfizer and Eisai to co-promote migraine medication in Japan. Pfizer Japan Inc. and Eisai Co., Ltd. have announced a collaboration to co-promote the oral calcitonin gene-related peptide (CGRP) receptor antagonist Nurtec(R) OD Tablet 75mg in Japan, beginning September 1, 2026. The medication, known generically as rimegepant sulfate hydrate, is designed for both acute treatment and prophylaxis of migraine. The partnership aims to enhance the dissemination of information regarding the appropriate use of Nurtec in treating migraine, a neurological disorder affecting approximately 8.4% of Japan's adult population. Pfizer will manage the development, manufacturing, distribution, and commercialization of Nurtec, while both companies will provide usage information to medical institutions. Migraine is a prevalent condition characterized by moderate-to-severe headaches and symptoms such as nausea, vomiting, and sensitivity to light and sound. The disorder significantly impacts daily life, with women aged 20-40 being the most affected demographic in Japan. Through this collaboration, Pfizer and Eisai intend to leverage their expertise and healthcare networks to promote the appropriate use of Nurtec, aiming to improve the quality of life for patients suffering from migraines. The initiative underscores the companies' commitment to addressing unmet medical needs and enhancing patient care in the neurology sector.

Eisai advances cold-chain pharma packaging capacity in UK. Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company. - Never miss a story with notifications - Browse free from any location or device. Media Packs Expand Your Reach With Its Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results! - Book a Conference Call

Eisai invests £48M in UK cold-chain pharma packaging hub. 19 Jun 2026 Key takeaways. * Eisai is investing approximately £48 million (US$63.5 million) at its Hatfield, UK, site to build cold-chain packaging and supply capabilities. * The project, supported by the UK Government's LSIMF, aims to strengthen domestic pharma manufacturing and improve supply resilience. * The investment will allow Eisai to bring more packaging operations in-house. Eisai, a Japanese pharmaceutical company, has announced an investment, supported by the UK government under the Life Sciences Innovative Manufacturing Fund (LSIMF), at its manufacturing site in Hatfield, UK, to establish supply chain and packaging capabilities for medicines that require cold-chain management. LSIMF is a capital grants scheme aiming to enhance life sciences manufacturing capabilities in the UK and improve supply resilience. The project is being implemented in multiple phases, with a total investment from Eisai of approximately £48 million (US$63.5 million). Haruo Naito, CEO at Eisai, says: "This strategic investment reflects our long-term commitment to strengthening resilient supply capabilities for our innovative medicines and pipeline products, while further deepening our long-standing relationship with the UK. We value the opportunity to work with the UK government in strengthening life sciences manufacturing and healthcare resilience for the future." Strengthen pharmaceutical manufacturing resilience. The investment is said to align with the UK government's policy to strengthen domestic pharmaceutical manufacturing. The Hatfield site aims to serve as a manufacturing hub serving multiple regions, including Europe, the Middle East, and Africa. Lord Vallance, Minister of State for Science, says: "Building world-class manufacturing capabilities here in the UK will secure the supply of vital medicines, including treatments for Alzheimer's disease, that can transform lives. Eisai's government-backed investment will also support the creation of new skilled jobs in Hatfield and is another example of the benefits of international companies investing in the UK - bolstering our reputation as a life sciences hub while growing our economy." According to Eisai, the investment will help expand the company's manufacturing capabilities, "broadening its role beyond traditional oral solid dose operations to support the packaging and supply of temperature-controlled medicines for injection and infusion." Moreover, the company is set to enhance supply stability and flexibility by transitioning from reliance on external contract manufacturers to an in-house packaging model. The investment covers facilities capable of handling temperature-controlled products, including the expansion of goods receipt and dispatch functions, construction of ambient and cold-chain warehouses, along with installation of packaging buildings and packaging lines. In addition, the site's advanced production flexibility, capacity for multilingual and small-batch packaging, and robust quality management systems will support Eisai's global supply network. In related pharmaceutical packaging manufacturing news, this month, Amcor boosted its healthcare packaging production capacity with a multi-million-dollar investment in its facility in Sira, Karnataka, India, and with a US$35 million investment to open a healthcare packaging coating facility in Subang Jaya, Selangor, Malaysia. Earlier this year, Sharp, a pharmaceutical packaging company, invested over €20 million (US$21.6 million) in its European packaging facilities in response to "strong market demand" for injectables.